Trial Profile
A Retrospective study to evaluate the safety, efficacy and to identify the clinical factors associated with the response in patients with Non-small-cell-lung-cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 14 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology